<DOC>
	<DOCNO>NCT01948011</DOCNO>
	<brief_summary>To investigate Racecadotril pharmacokinetic linearity single oral administration 10 , 30 60 mg suspension . To evaluate comparative bioavailability new Racecadotril formulation ( suspension ) versus reference sachet formulation ( granule )</brief_summary>
	<brief_title>Racecadotril Suspension Linearity Study &amp; Comparative Bioavailability Versus Granules</brief_title>
	<detailed_description>This single center , open-label , single oral dose , 4-period cross-over study assess bioequivalence new formulation ( suspension ) healthy male volunteer .</detailed_description>
	<mesh_term>Racecadotril</mesh_term>
	<mesh_term>Thiorphan</mesh_term>
	<criteria>Healthy male , 18 45 year old , certify normal comprehensive clinical assessment ( detailed medical history complete physical examination ) , arterial blood pressure ( BP ) , heart rate ( HR ) , ECG laboratory investigation ( haematological , blood chemistry test , urinalysis ) , result within normal range and/ judge investigator clinically acceptable healthy subject , Body Mass Index ( BMI ) 18 28 kg/m2 . History cardiovascular , pulmonary gastrointestinal , hepatic , renal , metabolic , haematological , neurological , psychiatric , systemic , infectious disease . Any condition , opinion Investigator , would jeopardize safety subject impact validity study result . Subject used drug include OTC product two week schedule administration study drug , except paracetamol ( maximum 1g/day ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>